Journal article
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative
E Stelloo, T Bosse, RA Nout, HJ Mackay, DN Church, HW Nijman, A Leary, RJ Edmondson, ME Powell, EJ Crosbie, HC Kitchener, L Mileshkin, PM Pollock, VT Smit, CL Creutzberg
Modern Pathology | NATURE PUBLISHING GROUP | Published : 2015
Abstract
This study aimed to investigate whether molecular analysis can be used to refine risk assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial cancer. TransPORTEC, an international consortium related to the PORTEC3 trial, was established for translational research in high-risk endometrial cancer. In this explorative study, routine molecular analyses were used to detect prognostic subgroups: p53 immunohistochemistry, microsatellite instability and POLE proofreading mutation. Furthermore, DNA was analyzed for hotspot mutations in 13 additional genes (BRAF, CDKNA2, CTNNB1, FBXW7, FGFR2, FGFR3, FOXL2, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, and PTEN) and prote..
View full abstractGrants
Awarded by KWF Kankerbestrijding
Funding Acknowledgements
This study was supported by the Dutch Cancer Society (KWF-UL2012-5719). We acknowledge all clinicians, technicians, scientists, and pathologists involved in the collaborating centers within the participating groups in the TransPORTEC consortium.